About Us

Home > About Histogen > Board

Board of Directors

Stephen Chang, Ph.D.

Stephen ChangDr. Stephen Chang is currently executive Chairman and Acting CEO of Histogen. He also leads the Office of the CEO, a committee that directs the day to day efforts of the Company. Dr. Chang serves on the Scientific Advisory Board or Board of Directors for GT Biopharma, Orphesus Therapeutics, Cloak Therapeutics, Aegis Therapeutics and Legacy Therapeutics. He also serves as Director of Research for One Med Research, a life science communications and analysis firm in NYC. He is an active a consultant for several small emerging life science companies in NYC area in the area of tools, technology and business strategy, and is an entrepreneur in residence at Rutgers and New York University.

Yizhuo Zhang

Yizhuo ZhangYizhuo Zhang is currently the director of Strategy and Investment Department of Huapont Life Sciences where he is in charge of all aspects of the group investment activities. He has successfully lead the acquisitions of several hospitals and biotech companies out of China and has years of experience in capital market. Yizhuo Zhang became the CEO of Huapont Huiyi Investment Co., in 2014 which is focused on investing and developing health-related Services.

Jonathan Jackson

Jonathan Jackson

A few years after completing his degree in Business Management in London, Jonathan Jackson set up his own company to develop commercial real estate in Central Europe. Over the last 20 years he has currently under development and developed more than 6,000,000 sqft of space. Since selling a portfolio of completed assets in early 2007 in one of the largest deals in Central Europe, Mr. Jackson has diversified and invested over $15M in different business sectors, both in the USA and Europe, with great success.

Brian Satz

Brian Satz

Brian M. Satz is an attorney and founder of Satz Law Group LLC in Fairfield, New Jersey. Mr. Satz has extensive experience representing clients in all aspects of corporate and commercial transactions as well as their day-to-day business matters. In particular, Mr. Satz has advised numerous investors and businesses in the biotech and life sciences industries and has been involved in the financing of many early stage companies. Prior to the founding of Satz Law Group, Mr. Satz spent the vast majority of his career working at large New York City based law firms.


David H. Crean, Ph.D.

David H. Crean, Ph.D.David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.

Histogen Inc. is a regenerative medicine company based on the commercialization of products manufactured by newborn human cells.
  • Broad range of markets, which are underserved and expected to grow
  • Rich product portfolio
  • Solutions without the use of embryonic stem cells or animal products
© Histogen Inc., CA 92121